Chiesi expands rare disease portfolio with Amryt Pharma acquisition
pharmaphorum
JANUARY 9, 2023
is to acquire the 2015-established Amryt Pharma Plc. Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 Biopharma and healthcare group Chiesi Farmaceutici S.p.A. on 6 th January.
Let's personalize your content